Celebrex Set For Rebound; Silver Lining For Pfizer After Bextra Pulled
Executive Summary
Celebrex is in a good position to reclaim its position as the leading anti-arthritic therapy following the conclusion of FDA's safety review of the non-steroidal anti-inflammatory drug class
You may also be interested in...
Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues
Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues
Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues
Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues
Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says
FDA is requiring labeling for non-steroidal anti-inflammatory drugs include a warning on skin reactions, in addition to a boxed warning on cardiovascular and gastrointestinal risk